Effects of Henagliflozin on Cardiac Structure in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Dialysis: The HELD-HF Randomized Controlled Trial

医学 射血分数 心脏病学 内科学 随机对照试验 心力衰竭 安慰剂 不利影响 腹膜透析 透析 射血分数保留的心力衰竭 冲程容积 利钠肽 心脏指数 脑利钠肽 临床试验 体质指数 血流动力学 舒张期
作者
Renhua Lu,Leyi Gu
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:36 (10S) 被引量:1
标识
DOI:10.1681/asn.2025yem71v7w
摘要

Background: Among patients undergoing dialysis, heart failure with preserved ejection fraction (HFpEF) is frequently observed and associated with increased mortality. This study assessed the safety and efficacy of long-term treatment with henagliflozin, a SGLT2 inhibitor, in improving cardiac structure in dialysis patients with HFpEF. Methods: In this randomized, double-blind, placebo-controlled trial (ChiCTR2300073169), patients undergoing haemodialysis or peritoneal dialysis with HFpEF (left ventricular ejection fraction ≥50%) were randomized (1:1) to receive henagliflozin 5 mg once daily or matching placebo, in addition to their usual therapy for 24 weeks.The primary outcome was the between-group difference in change in left ventricular mass index (LVMI) from baseline to week 24, as measured by echocardiography. Secondary outcomes were the changes in left atrial volume index (LAVI), E/e’, e’, N-terminal pro-brain natriuretic peptide (NT-proBNP) after 24 weeks of treatment. Adverse events were recorded until 28 weeks after enrollment. Efficacy analyses were conducted according to the full analysis set. Results: From September 2023 to February 2024, 112 patients were randomized. From baseline to week 24, the mean change in LVMI was –3.38 ± 12.00 g/m2 in the henagliflozin group and 2.08 ± 12.25 g/m2 in the placebo group, with a between-group difference of -5.38 g/m2(95%CI, -10.12 to -0.64 g/m2; p=0.026) (table 1). Sensitivity analysis using last observation carried forward imputation and per protocol populations showed similar results, supporting a significant reduction in LVMI with henagliflozin versus placebo. No differences were observed between the two groups in secondary efficacy outcomes, including LAVI, E/e’, e’, and NT-proBNP. The incidence of adverse events was similar between the two groups (35.7% in the henagliflozin group and 32.1% in the placebo group). Conclusion: Henagliflozin significantly reduced LVMI compared with placebo in patients with HFpEF on dialysis and was safe over 24 weeks of treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
顾矜的应助被美满的灵安采纳,获得30
刚刚
linger发布了新的文献求助10
刚刚
刚刚
机智凝海完成签到,获得积分10
1秒前
hahaqi完成签到,获得积分10
1秒前
2秒前
2秒前
Ich发布了新的文献求助10
2秒前
爆米花的应助被Fearless采纳,获得10
3秒前
4秒前
桐桐的应助被yyzq采纳,获得10
4秒前
5秒前
王甜甜完成签到,获得积分10
5秒前
cq完成签到,获得积分20
5秒前
6秒前
6秒前
6秒前
FashionBoy的应助被雷昊采纳,获得10
6秒前
sss发布了新的文献求助10
7秒前
三语掾完成签到,获得积分10
7秒前
8秒前
8秒前
万能图书馆的应助被nihao采纳,获得10
9秒前
9秒前
爱学习的结香酱完成签到,获得积分10
9秒前
Roy完成签到,获得积分10
9秒前
9秒前
10秒前
zz完成签到,获得积分20
10秒前
风语过发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
可靠的马丁的应助被zq采纳,获得30
11秒前
11秒前
上官若男的应助被Wenlia采纳,获得30
11秒前
迟静发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163000
求助须知:如何正确求助?哪些是违规求助? 9557323
关于积分的说明 21739034
捐赠科研通 7753593
什么是DOI,文献DOI怎么找? 3427993
关于科研通互助平台的介绍 2552789
邀请新用户注册赠送积分活动 2472644